Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adicet Bio Inc ACET

Healthcare Biotechnology
Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential... see more

Recent & Breaking News (NDAQ:ACET)

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Business Wire 6 days ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire 11 days ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Business Wire October 28, 2025

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Business Wire October 16, 2025

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Business Wire October 7, 2025

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Business Wire October 7, 2025

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 30, 2025

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Business Wire September 2, 2025

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 29, 2025

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Business Wire August 7, 2025

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Business Wire August 5, 2025

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Business Wire July 24, 2025

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Business Wire May 21, 2025

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Business Wire May 6, 2025

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 30, 2025

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Business Wire April 30, 2025

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Business Wire April 28, 2025

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Business Wire April 17, 2025

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 31, 2025

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire March 31, 2025